Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear cap-binding protein subunit 1 (NCBP1, also known as CBP80) is a large protein component of the nuclear cap-binding complex (CBC) in eukaryotic cells[1][3][4]. The CBC binds to the 5' cap of newly synthesized pre-mRNA, playing a crucial role in mRNA biogenesis, including splicing, 3'-end formation, nuclear export, and protection from nuclease degradation[1][4][5]. NCBP1 itself does not bind RNA directly but stabilizes the CBC’s high-affinity binding through interaction with NCBP2 (CBP20) and recruits processing factors[1][3][4][5]. It is also an adaptor for alternative CBC formation with NCBP3 during stress conditions[5][7]. CBC-dependent processes managed by NCBP1 are essential for normal cell growth and viability; depletion leads to loss of cell proliferation and widespread misregulation of genes[5][7]. NCBP1 is not currently a therapeutic target or biomarker, and its dysfunction would pose major safety concerns due to pan-regulation of gene expression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear cap-binding protein subunit 1 (NCBP1).